BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY
The article presents data on unique worldwide experience of biologic agents use in pediatric rheumatology. 433 children with different types of juvenile arthritis (JA) were treated with biologic drugs in Rheumatological Department of Scientific Center of Children’s Health, Russian Academy of Medical...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2011-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/533 |
| _version_ | 1797697582335524864 |
|---|---|
| author | A. A. Baranov Ye. I. Alekseyeva S. I. Valiyeva T. M. Bzarova R. V. Denisova Ye. G. Chistyakova T. V. Sleptsova Ye. V. Mitenko |
| author_facet | A. A. Baranov Ye. I. Alekseyeva S. I. Valiyeva T. M. Bzarova R. V. Denisova Ye. G. Chistyakova T. V. Sleptsova Ye. V. Mitenko |
| author_sort | A. A. Baranov |
| collection | DOAJ |
| description | The article presents data on unique worldwide experience of biologic agents use in pediatric rheumatology. 433 children with different types of juvenile arthritis (JA) were treated with biologic drugs in Rheumatological Department of Scientific Center of Children’s Health, Russian Academy of Medical Sciences from November 2002 to September 2010: 270 patients received infliximab, 74 — adalimumab, 55 — rituximab, 34 — tocilizumab. Results of a study showed that differentiated biological therapy unlike classic immunosuppressive agents (methotrexate, cyclosporine, leflunomide, etc.) results in clinical and laboratory remission in 70% patients with JA and decrease of disease’s activity in 20% of children in one year. Treatment with genetically engineered biologic drugs increase quality of life of children with JA and their families, provides normal growth and development of patients, and changes a prognosis of this previously incurable autoimmune disease. |
| first_indexed | 2024-03-12T03:42:16Z |
| format | Article |
| id | doaj.art-1807f89448ad46579d8cc9dcfacd033d |
| institution | Directory Open Access Journal |
| issn | 1682-5527 1682-5535 |
| language | English |
| last_indexed | 2024-03-12T03:42:16Z |
| publishDate | 2011-01-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj.art-1807f89448ad46579d8cc9dcfacd033d2023-09-03T13:02:27Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352011-01-01101516533BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGYA. A. Baranov0Ye. I. Alekseyeva1S. I. Valiyeva2T. M. Bzarova3R. V. Denisova4Ye. G. Chistyakova5T. V. Sleptsova6Ye. V. Mitenko7Научный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваНаучный центр здоровья детей РАМН, МоскваНаучный центр здоровья детей РАМН, МоскваThe article presents data on unique worldwide experience of biologic agents use in pediatric rheumatology. 433 children with different types of juvenile arthritis (JA) were treated with biologic drugs in Rheumatological Department of Scientific Center of Children’s Health, Russian Academy of Medical Sciences from November 2002 to September 2010: 270 patients received infliximab, 74 — adalimumab, 55 — rituximab, 34 — tocilizumab. Results of a study showed that differentiated biological therapy unlike classic immunosuppressive agents (methotrexate, cyclosporine, leflunomide, etc.) results in clinical and laboratory remission in 70% patients with JA and decrease of disease’s activity in 20% of children in one year. Treatment with genetically engineered biologic drugs increase quality of life of children with JA and their families, provides normal growth and development of patients, and changes a prognosis of this previously incurable autoimmune disease.https://vsp.spr-journal.ru/jour/article/view/533детиревматологиябиологическая терапия |
| spellingShingle | A. A. Baranov Ye. I. Alekseyeva S. I. Valiyeva T. M. Bzarova R. V. Denisova Ye. G. Chistyakova T. V. Sleptsova Ye. V. Mitenko BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY Вопросы современной педиатрии дети ревматология биологическая терапия |
| title | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY |
| title_full | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY |
| title_fullStr | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY |
| title_full_unstemmed | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY |
| title_short | BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY |
| title_sort | biologic therapy in pediatric rheumatology |
| topic | дети ревматология биологическая терапия |
| url | https://vsp.spr-journal.ru/jour/article/view/533 |
| work_keys_str_mv | AT aabaranov biologictherapyinpediatricrheumatology AT yeialekseyeva biologictherapyinpediatricrheumatology AT sivaliyeva biologictherapyinpediatricrheumatology AT tmbzarova biologictherapyinpediatricrheumatology AT rvdenisova biologictherapyinpediatricrheumatology AT yegchistyakova biologictherapyinpediatricrheumatology AT tvsleptsova biologictherapyinpediatricrheumatology AT yevmitenko biologictherapyinpediatricrheumatology |